Results 11 to 20 of about 311 (111)

Long‐Acting Growth Hormone Versus Daily Growth Hormone for Growth Hormone Deficiency Patients: A Network Meta‐Analysis of Clinical Trials [PDF]

Endocrinology, Diabetes & Metabolism
Introduction Current guidelines recognize daily recombinant human growth hormone (rhGH) as standard care and long‐acting growth hormone (LAGH) as an alternative for paediatric growth hormone deficiency (CHD).
Amir Abadi, Usra Ghanem, Hamid Ghanem, Ahmed Jalal Sawafta, Ayah Abulehia, Mohammed Ataya, Rahma Nairat, Alhammam Mohammad Sammour, Hazem Ayesh   +8 more
doaj   +4 more sources

Patients With Growth-Related Disorders and Caregivers Prefer the Somapacitan Device to the Somatrogon Device: Results From a Randomized Crossover Study Assessing Device Preference and Ease of Use Following Simulated Injections [PDF]

Medical Devices: Evidence and Research
Shahid Akhtar,1 Birgitte Berg,2 Johan Medina,3 Maya Nicole Gonczi,4 Sophie Hamilton,5 Emily Hildebrand,4 Nicky Kelepouris,6 Jesper Skov Neergaard,7 Claus Sværke,8 Gitte Ter-Borch,2 Niklas Kahr Rasmussen3 1Devices & Digital Health, Novo Nordisk A/S ...
Shahid Akhtar, Claus Sværke, Gitte Ter-Borch   +2 more
exaly   +5 more sources

Injection-site pain after switching from somatrogon to somapacitan in children reporting pain or discomfort during once-weekly growth hormone therapy: a prospective single-arm switch study [PDF]

Frontiers in Endocrinology
BackgroundOnce-weekly growth hormone (GH) formulations, such as somatrogon and somapacitan, may reduce the burden of treatment, but injection-site pain can affect treatment preference.
Hideyuki Iwayama, Hideyuki Iwayama, Kohei Kawahara, Kohei Kawahara, Sachiko Kitagawa, Sachiko Kitagawa, Ryosuke Miyamoto, Junko Takagi, Yoshinori Ito, Akihisa Okumura   +9 more
doaj   +3 more sources

New directions in growth hormone treatment in children [PDF]

Pediatric Endocrinology, Diabetes and Metabolism
This paper reviews clinical-trial evidence on the use of long-acting growth hormone (LAGH) preparations in children. Three LAGH products have been approved in Europe and the United States for paediatric growth hormone deficiency (GHD): lonapegsomatropin,
Renata Stawerska
doaj   +3 more sources

Long-acting growth hormones: innovations in treatment and guidance on patient selection in pediatric growth hormone deficiency [PDF]

Annals of Pediatric Endocrinology & Metabolism
Long-acting growth hormones (LAGHs) represent a significant advancement in the treatment of pediatric GH deficiency, offering an alternative to daily recombinant human GH (rhGH) therapy.
Chiara Rodaro, Gianluca Tamaro, Elena Faleschini, Gianluca Tornese   +3 more
doaj   +4 more sources

Long-acting growth hormone in the treatment of growth hormone deficiency in children: a systematic literature review and network meta-analysis [PDF]

Scientific Reports
The purpose of this study is to compare the relative efficacy and safety of long-acting growth hormone (LAGH) as a growth hormone replacement therapy in prepubertal children with growth hormone deficiency (GHD).
Jianfang Zhu, Ke Yuan, Sunita Rana, Satya Lavanya Jakki, Amit Subray Bhat, Li Liang, Chunlin Wang   +6 more
doaj   +3 more sources

Severe Lipoatrophy in a Growth Hormone Deficient Toddler Girl Treated with a Non-Pegylated Long-Acting Growth Hormone [PDF]

Children
Background: Recombinant growth hormone (rhGH) has been used since 1985 to treat growth hormone (GH)-induced short stature, typically associated with transient adverse events. However, lipoatrophy, characterized by irreversible damage to subcutaneous fat,
Atilla Büyükgebiz, And Demir
doaj   +3 more sources

IGF-1 Assessment During Weekly Somatrogon Treatment in Pediatric Patients With GH Deficiency [PDF]

Journal of the Endocrine Society
Abstract Context In patients with GH deficiency (GHD) receiving GH treatment, IGF-1 concentrations are used by physicians to monitor treatment safety and efficacy and guide dosing decisions. Somatrogon is a long-acting GH approved as a once-weekly treatment for pediatric GHD.
Cheri L Deal, Satyaprakash Nayak, Ron Rosenfeld   +2 more
exaly   +4 more sources

First 100 patients receiving long-acting growth hormone therapy: real-world evaluation from INSIGHTS-GHT registry [PDF]

Orphanet Journal of Rare Diseases
The development of long-acting growth hormone (LAGH) formulations offers a promising approach to reduce injection frequency and to improve adherence in growth hormone deficiency (GHD) treatment.
Joachim Woelfle, I. Kreitschmann-Andermahr, C. J. Strasburger, D. B. Pittrow, C. Pausch, D. Schnabel   +5 more
doaj   +3 more sources

Detection of the GH Analogue Redalsomatropin Alfa in Sports Drug Testing: Immunological Approaches and LC‐HRMS/MS [PDF]

Drug Testing and Analysis, Volume 18, Issue 7, Page 811-820, July 2026.
After evaluating the compatibility of the GH analogue redalsomatropin alfa with approved doping control immunoassays for rhGH, it was implemented into the existing detection method for somatrogon employing affinity purification with GHR‐Fc‐conjugated magnetic beads, tryptic digestion, and LC‐HRMS/MS to allow for a specific and sensitive detection ...
Katja Walpurgis, Andreas Thomas, Jasmin Thelen, Bettina Majer, Maneera Al‐Jaber, Wadha Abushareeda, Mario Thevis   +6 more
wiley   +2 more sources